• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于递归分割分析的局部复发鼻咽癌患者再放疗指导预后模型的建立与验证。

Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients.

机构信息

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, PR China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

出版信息

Radiother Oncol. 2022 Mar;168:61-68. doi: 10.1016/j.radonc.2022.01.026. Epub 2022 Jan 29.

DOI:10.1016/j.radonc.2022.01.026
PMID:35101468
Abstract

OBJECTIVE

In this study, we aimed to establish and validate an integrated prognostic model for locally recurrent nasopharyngeal carcinoma (lrNPC) patients, and evaluate the benefit of re-radiotherapy (re-RT) in patients with different risk levels.

MATERIALS AND METHODS

In total, 531 patients with lrNPC were retrospectively reviewed in this study, including 271 patients from 2006 to 2012 as the training cohort and 260 patients from 2013 to 2016 as the validation cohort. Overall survival (OS) was the primary endpoint. Multivariate analysis was performed to select the significant prognostic factors (P < 0.05). A prognostic model for OS was derived by recursive partitioning analysis (RPA) combining independent predictors using the algorithm of optimized binary partition.

RESULTS

Three independent prognostic factors (age, relapsed T [rT] stage, and Epstein-Barr virus [EBV] DNA) were identified from multivariate analysis. Five prognostic groups were derived from an RPA model that combined rT stage and EBV DNA. After further pair-wise comparisons of survival outcome in each group, three risk groups were generated. We investigated the role of re-RT in different risk groups, and found that re-RT could benefit patients in the low (P < 0.001) and intermediate-risk subgroups (P = 0.017), while no association between re-RT and survival benefit was found in the high-risk subgroup (P = 0.328). The results of risk stratification and re-RT efficacy were verified in the validation cohort.

CONCLUSION

Age, rT stage and EBV DNA were identified as independent predictors for lrNPC. We established an integrated RPA-based prognostic model for OS incorporating rT stage and EBV DNA, which could guide individual treatment for lrNPC.

摘要

目的

本研究旨在建立并验证局部复发鼻咽癌(lrNPC)患者的综合预后模型,并评估不同风险水平患者再次放疗(re-RT)的获益。

材料与方法

本研究回顾性分析了 531 例 lrNPC 患者,其中 271 例来自 2006 年至 2012 年的训练队列,260 例来自 2013 年至 2016 年的验证队列。总生存(OS)为主要终点。多变量分析用于选择显著的预后因素(P<0.05)。使用优化二分划分算法,通过递归分区分析(RPA)将独立预测因子结合起来,得出 OS 的预后模型。

结果

多变量分析确定了 3 个独立的预后因素(年龄、复发 T 期[rT 期]和 EBV DNA)。RPA 模型将 rT 期和 EBV DNA 结合起来,得出 5 个预后组。进一步对每组生存结果进行两两比较,得出 3 个风险组。我们研究了 re-RT 在不同风险组中的作用,发现 re-RT 可使低危(P<0.001)和中危组(P=0.017)患者获益,而高危组中 re-RT 与生存获益之间无关联(P=0.328)。在验证队列中验证了风险分层和 re-RT 疗效的结果。

结论

年龄、rT 期和 EBV DNA 被确定为 lrNPC 的独立预测因素。我们建立了一个基于 RPA 的综合 OS 预后模型,纳入了 rT 期和 EBV DNA,可指导 lrNPC 的个体化治疗。

相似文献

1
Establishment and validation of a recursive partitioning analysis based prognostic model for guiding re-radiotherapy in locally recurrent nasopharyngeal carcinoma patients.基于递归分割分析的局部复发鼻咽癌患者再放疗指导预后模型的建立与验证。
Radiother Oncol. 2022 Mar;168:61-68. doi: 10.1016/j.radonc.2022.01.026. Epub 2022 Jan 29.
2
Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.将放疗后血浆 Epstein-Barr 病毒 DNA 与 TNM 分期相结合,对鼻咽癌辅助治疗进行风险分层。
Ann Oncol. 2020 Jun;31(6):769-779. doi: 10.1016/j.annonc.2020.03.289. Epub 2020 Mar 23.
3
Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.局部复发鼻咽癌治疗前血浆 Epstein-Barr 病毒 DNA 的临床特征及其预后价值。
Cancer Med. 2019 Aug;8(10):4633-4643. doi: 10.1002/cam4.2339. Epub 2019 Jul 3.
4
Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.诱导化疗后循环 EBV-DNA 水平对鼻咽癌患者的预后价值:递归分区风险分层分析。
Radiother Oncol. 2023 Aug;185:109721. doi: 10.1016/j.radonc.2023.109721. Epub 2023 May 25.
5
Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.提出的修改和纳入血浆 Epstein-Barr 病毒 DNA 可改善与 Epstein-Barr 病毒相关的鼻咽癌的 TNM 分期系统。
Cancer. 2019 Jan 1;125(1):79-89. doi: 10.1002/cncr.31741. Epub 2018 Oct 23.
6
Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.基于递归分区分析的初治转移性鼻咽癌的预后亚组和辅助局部区域放疗的临床决策制定:一项回顾性研究。
Radiat Oncol. 2023 Jan 21;18(1):15. doi: 10.1186/s13014-022-02168-2.
7
Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.选择和验证接受调强放射治疗的老年鼻咽癌(NPC)患者中的化疗受益人群:一项大型真实世界研究。
Radiat Oncol. 2022 Aug 8;17(1):138. doi: 10.1186/s13014-022-02095-2.
8
Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.评估纳入 EBV-DNA 状态后常规 TNM 分期组中 EBV 相关鼻咽癌的生存模型性能。
JAMA Netw Open. 2021 Sep 1;4(9):e2124721. doi: 10.1001/jamanetworkopen.2021.24721.
9
The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.将治疗前血浆 Epstein-Barr 病毒 DNA 纳入第八版鼻咽癌 TNM 分期分类中。
Int J Cancer. 2019 Apr 1;144(7):1713-1722. doi: 10.1002/ijc.31856. Epub 2018 Dec 24.
10
Integrating Postradiotherapy MRI-Detected Lymph Node Necrosis and Pre- and Posttreatment Epstein-Barr Virus-DNA for Risk Stratification in Nasopharyngeal Carcinoma.将放疗后 MRI 检测到的淋巴结坏死与治疗前后 EBV-DNA 整合,用于鼻咽癌的风险分层。
J Magn Reson Imaging. 2023 Jul;58(1):108-119. doi: 10.1002/jmri.28515. Epub 2022 Nov 3.

引用本文的文献

1
Recursive partitioning staging system based on the log odds of the negative lymph node/T stage ratio in colon mucinous adenocarcinoma.基于结肠黏液腺癌阴性淋巴结/T分期比值对数优势比的递归划分分期系统。
Front Immunol. 2024 Dec 20;15:1472620. doi: 10.3389/fimmu.2024.1472620. eCollection 2024.
2
Prognostic value of immune-inflammatory and nutrition indicators in non-metastatic nasopharyngeal carcinoma with negative plasma Epstein-Barr virus DNA.血浆EB病毒DNA阴性的非转移性鼻咽癌中免疫炎症和营养指标的预后价值
Ther Adv Med Oncol. 2024 Oct 14;16:17588359241286489. doi: 10.1177/17588359241286489. eCollection 2024.
3
Patterns and Prognosis of Local Recurrence of Nasopharyngeal Carcinoma after Intensity-modulated Radiotherapy.
调强放疗后鼻咽癌局部复发的模式与预后
J Cancer. 2024 Jan 1;15(2):456-465. doi: 10.7150/jca.88148. eCollection 2024.
4
Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification.老年鼻咽癌患者总生存预后模型:识别治疗前风险分层的递归分区分析。
Radiat Oncol. 2023 Jun 23;18(1):104. doi: 10.1186/s13014-023-02272-x.
5
Impact of Radiotherapy Combined With Chemotherapy on Long-Term Outcomes of Patients With Recurrent Nasopharyngeal Carcinoma.放疗联合化疗对复发性鼻咽癌患者长期结局的影响。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231155721. doi: 10.1177/15330338231155721.